David Launay

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8062229/publications.pdf

Version: 2024-02-01

298 papers 18,332 citations

14614 66 h-index 17055 122 g-index

392 all docs 392 docs citations

times ranked

392

15136 citing authors

#	Article	IF	CITATIONS
1	Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis. New England Journal of Medicine, 2014, 371, 1771-1780.	13.9	842
2	Update of EULAR recommendations for the treatment of systemic sclerosis. Annals of the Rheumatic Diseases, 2017, 76, 1327-1339.	0.5	794
3	Eosinophilic granulomatosis with polyangiitis (Churgâ€Strauss): Clinical characteristics and longâ€term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis and Rheumatism, 2013, 65, 270-281.	6.7	670
4	Early detection of pulmonary arterial hypertension in systemic sclerosis: A French nationwide prospective multicenter study. Arthritis and Rheumatism, 2005, 52, 3792-3800.	6.7	656
5	Azathioprine or Methotrexate Maintenance for ANCA-Associated Vasculitis. New England Journal of Medicine, 2008, 359, 2790-2803.	13.9	603
6	High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood, 2012, 120, 2700-2703.	0.6	589
7	Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis. JAMA - Journal of the American Medical Association, 2014, 311, 2490.	3 . 8	566
8	Clinical picture and treatment of 2212 patients with common variable immunodeficiency. Journal of Allergy and Clinical Immunology, 2014, 134, 116-126.e11.	1.5	512
9	Clinical features and outcomes in 348 patients with polyarteritis nodosa: A systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French vasculitis study group database. Arthritis and Rheumatism, 2010, 62, 616-626.	6.7	483
10	Immunosuppressive therapy in lupus―and mixed connective tissue disease–associated pulmonary arterial hypertension: A retrospective analysis of twentyâ€three cases. Arthritis and Rheumatism, 2008, 58, 521-531.	6.7	321
11	Screening for pulmonary arterial hypertension in patients with systemic sclerosis: Clinical characteristics at diagnosis and longâ€term survival. Arthritis and Rheumatism, 2011, 63, 3522-3530.	6.7	291
12	Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Annals of the Rheumatic Diseases, 2012, 71, 1355-1360.	0.5	275
13	Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients. Annals of the Rheumatic Diseases, 2009, 68, 1878-1884.	0.5	227
14	Survival and Prognostic Factors in Systemic Sclerosis–Associated Pulmonary Hypertension: A Systematic Review and Metaâ€Analysis. Arthritis and Rheumatism, 2013, 65, 2412-2423.	6.7	205
15	The threeâ€year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis and Rheumatism, 2009, 60, 1831-1839.	6.7	179
16	Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey. Blood, 2012, 119, 5996-6004.	0.6	175
17	Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. Rheumatology, 2016, 55, 291-300.	0.9	170
18	Characteristics of Joint Involvement and Relationships with Systemic Inflammation in Systemic Sclerosis: Results from the EULAR Scleroderma Trial and Research Group (EUSTAR) Database. Journal of Rheumatology, 2010, 37, 1488-1501.	1.0	161

#	Article	IF	Citations
19	Pulmonary Arterial Hypertension: A Rare Complication of Primary Sjögren Syndrome. Medicine (United) Tj ETQq1	1.0.78431	14 rgBT /0\ 160
20	Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). Annals of the Rheumatic Diseases, 2013, 72, 1786-1792.	0.5	160
21	Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinerAIR-Sclerodermie study. Rheumatology, 2008, 48, 304-308.	0.9	148
22	Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study. Journal of Rheumatology, 2007, 34, 2423-30.	1.0	148
23	Diagnosis and Classification of Systemic Sclerosis. Clinical Reviews in Allergy and Immunology, 2011, 40, 78-83.	2.9	142
24	Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party. Blood, 2011, 118, 1693-1698.	0.6	140
25	Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides. Annals of the Rheumatic Diseases, 2018, 77, 1150-1156.	0.5	139
26	Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. Annals of the Rheumatic Diseases, 2013, 72, 1940-1946.	0.5	128
27	High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. Journal of Rheumatology, 2006, 33, 1789-801.	1.0	126
28	High-dose intravenous immunoglobulins dramatically reverse systemic capillary leak syndrome. Critical Care Medicine, 2008, 36, 2184-2187.	0.4	124
29	Determinants of Hydroxychloroquine Blood Concentration Variations in Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2015, 67, 2176-2184.	2.9	118
30	Is Pulmonary Arterial Hypertension Really a Late Complication of Systemic Sclerosis?. Chest, 2009, 136, 1211-1219.	0.4	117
31	Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature. Arthritis Research and Therapy, 2019, 21, 86.	1.6	114
32	Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study. Annals of the Rheumatic Diseases, 2016, 75, 1009-1015.	0.5	112
33	Digital ulcers predict a worse disease course in patients with systemic sclerosis. Annals of the Rheumatic Diseases, 2016, 75, 681-686.	0.5	111
34	Systemic sclerosis–related pulmonary hypertension associated with interstitial lung disease: Impact of pulmonary arterial hypertension therapies. Arthritis and Rheumatism, 2011, 63, 2456-2464.	6.7	109
35	Efficacy of rituximab in primary Sjögren's syndrome with peripheral nervous system involvement: results from the AIR registry. Annals of the Rheumatic Diseases, 2012, 71, 84-87.	0.5	109
36	Pulmonary hypertension in antisynthetase syndrome: prevalence, aetiology and survival. European Respiratory Journal, 2013, 42, 1271-1282.	3.1	108

#	Article	IF	CITATIONS
37	Immunological profile in primary Sjögren syndrome. Autoimmunity Reviews, 2010, 9, 595-599.	2.5	103
38	Longâ€Term Outcomes Among Participants in the WEGENT Trial of Remissionâ€Maintenance Therapy for Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis. Arthritis and Rheumatology, 2016, 68, 690-701.	2.9	101
39	Recovery from deafness in a patient with Muckle-Wells syndrome treated with anakinra. Arthritis and Rheumatism, 2006, 54, 1697-1700.	6.7	100
40	Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. Journal of Rheumatology, 2008, 35, 1064-72.	1.0	99
41	The Lymphoid Variant of Hypereosinophilic Syndrome. Medicine (United States), 2014, 93, 255-266.	0.4	98
42	Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: Data from the French Autoimmunity and Rituximab registry. Arthritis Care and Research, 2010, 62, 1787-1795.	1.5	97
43	Pulmonary hypertension in systemic sclerosis: different phenotypes. European Respiratory Review, 2017, 26, 170056.	3.0	97
44	Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry. Annals of the Rheumatic Diseases, 2012, 71, 718-721.	0.5	96
45	Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. Annals of the Rheumatic Diseases, 2015, 74, 1124-1131.	0.5	96
46	Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler's syndrome: A french multicenter study. Autoimmunity Reviews, 2014, 13, 1035-1041.	2.5	94
47	Articular manifestations in primary Sjogren's syndrome: clinical significance and prognosis of 188 patients. Rheumatology, 2010, 49, 1164-1172.	0.9	93
48	Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study. Annals of the Rheumatic Diseases, 2016, 75, 103-109.	0.5	93
49	Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology, 2010, 49, 490-500.	0.9	91
50	Hydroxychloroquine-Induced Pigmentation in Patients With Systemic Lupus Erythematosus. JAMA Dermatology, 2013, 149, 935.	2.0	91
51	Systemic sclerosis: state of the art on clinical practice guidelines. RMD Open, 2019, 4, e000782.	1.8	91
52	Clinical Characteristics and Survival in Systemic Sclerosis-Related Pulmonary Hypertension Associated With Interstitial Lung Disease. Chest, 2011, 140, 1016-1024.	0.4	89
53	Hereditary angioedema with C1 inhibitor deficiency: clinical presentation and quality of life of 193 French patients. Annals of Allergy, Asthma and Immunology, 2013, 111, 290-294.	0.5	88
54	Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience. Blood Advances, 2022, 6, 998-1003.	2.5	88

#	Article	lF	CITATIONS
55	A descriptive and prognostic study of systemic sclerosis-associated myopathies. Annals of the Rheumatic Diseases, 2009, 68, 1474-1477.	0.5	87
56	Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease. Journal of Rheumatology, 2007, 34, 1005-11.	1.0	84
57	A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. Annals of the Rheumatic Diseases, 2016, 75, 163-169.	0.5	82
58	Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients. Lupus, 2008, 17, 11-15.	0.8	80
59	Misdiagnosis trends in patients with hereditary angioedema from the real-world clinical setting. Annals of Allergy, Asthma and Immunology, 2016, 117, 394-398.	0.5	78
60	Dermatomyositis With or Without Anti-Melanoma Differentiation-Associated Gene 5 Antibodies. American Journal of Pathology, 2016, 186, 691-700.	1.9	78
61	Active Immunological Profile Is Associated with Systemic Sjögren's Syndrome. Journal of Clinical Immunology, 2011, 31, 840-847.	2.0	76
62	Prevalence of Anti–RNA Polymerase III Antibodies in Systemic Sclerosis: New Data From a French Cohort and a Systematic Review and Metaâ€Analysis. Arthritis and Rheumatology, 2014, 66, 407-417.	2.9	76
63	Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. Arthritis and Rheumatology, 2019, 71, 1553-1570.	2.9	75
64	Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review. Autoimmunity Reviews, 2018, 17, 582-587.	2.5	74
65	Benefits of progestin contraception in nonâ€allergic angioedema. Clinical and Experimental Allergy, 2013, 43, 475-482.	1.4	70
66	Central nervous system involvement in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): Report of 26 patients and review of the literature. Autoimmunity Reviews, 2017, 16, 963-969.	2.5	70
67	Design, synthesis and biological evaluation of 2-substituted quinolines as potential antileishmanial agents. European Journal of Medicinal Chemistry, 2013, 69, 527-536.	2.6	68
68	Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis. Annals of the Rheumatic Diseases, 2016, 75, 1743-1748.	0.5	68
69	Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease. PLoS ONE, 2017, 12, e0181692.	1.1	68
70	Pulmonary Arterial Hypertension Associated With Systemic Lupus Erythematosus. Chest, 2018, 153, 143-151.	0.4	68
71	Idiopathic hypertrophic cranial pachymeningitis treated by oral methotrexate: a case report and review of literature. Rheumatology International, 2008, 28, 713-718.	1.5	66
72	Selective involvement of ERK and JNK mitogen-activated protein kinases in early rheumatoid arthritis (1987 ACR criteria compared to 2010 ACR/EULAR criteria): a prospective study aimed at identification of diagnostic and prognostic biomarkers as well as therapeutic targets. Annals of the Rheumatic Diseases, 2012, 71, 415-423.	0.5	65

#	Article	IF	Citations
73	ASXL1 but Not TET2 Mutations Adversely Impact Overall Survival of Patients Suffering Systemic Mastocytosis with Associated Clonal Hematologic Non-Mast-Cell Diseases. PLoS ONE, 2014, 9, e85362.	1.1	65
74	Myopathies related to systemic sclerosis: a case–control study of associated clinical and immunological features. Scandinavian Journal of Rheumatology, 2010, 39, 498-505.	0.6	64
75	A nationwide study of acquired C1-inhibitor deficiency in France. Medicine (United States), 2016, 95, e4363.	0.4	64
76	Mast cells' involvement in inflammation pathways linked to depression: evidence in mastocytosis. Molecular Psychiatry, 2016, 21, 1511-1516.	4.1	64
77	Inhibition of forkhead box class O family member transcription factors in rheumatoid synovial tissue. Arthritis and Rheumatism, 2007, 56, 2180-2191.	6.7	63
78	Pulmonary manifestations of Sjögren's syndrome. Presse Medicale, 2011, 40, e71-e86.	0.8	61
79	Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension. European Respiratory Journal, 2018, 52, 1800678.	3.1	60
80	Prognosis Assessment of Cardiac Involvement in Systemic AL Amyloidosis by Magnetic Resonance Imaging. American Journal of Medicine, 2010, 123, 864-868.	0.6	59
81	Prognostic factors of survival in patients with non-infectious mixed cryoglobulinaemia vasculitis: data from 242 cases included in the CryoVas survey. Annals of the Rheumatic Diseases, 2013, 72, 374-380.	0.5	59
82	Tranexamic acid as maintenance treatment for non-histaminergic angioedema: analysis of efficacy and safety in 37 patients. Clinical and Experimental Immunology, 2014, 178, 112-117.	1.1	58
83	Inflammatory Arthritis in Patients With Myelodysplastic Syndromes. Medicine (United States), 2014, 93, 1-10.	0.4	58
84	Altered B lymphocyte homeostasis and functions in systemic sclerosis. Autoimmunity Reviews, 2018, 17, 244-255.	2.5	58
85	Triggers and Prodromal Symptoms of Angioedema Attacks in Patients With Hereditary Angioedema. Journal of Investigational Allergology and Clinical Immunology, 2016, 26, 383-386.	0.6	57
86	Is there a role for TNF $\hat{l}\pm$ antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique. Clinical and Experimental Rheumatology, 2011, 29, S40-5.	0.4	57
87	Nitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasis. Journal of Antimicrobial Chemotherapy, 2015, 70, 518-527.	1.3	56
88	Characterization of discriminant human brain antigenic targets in neuropsychiatric systemic lupus erythematosus using an immunoproteomic approach. Arthritis and Rheumatism, 2007, 56, 3420-3432.	6.7	54
89	Enzymatic Assays for the Diagnosis of Bradykinin-Dependent Angioedema. PLoS ONE, 2013, 8, e70140.	1.1	54
90	Lower vitamin D levels are associated with higher systemic lupus erythematosus activity, but not predictive of disease flare-up. Lupus Science and Medicine, 2014, 1, e000027.	1.1	54

#	Article	lF	Citations
91	Midostaurin in Advanced Systemic Mastocytosis. New England Journal of Medicine, 2016, 374, 2605-2606.	13.9	54
92	Antiphospholipid antibodies in primary Sjögren's syndrome: prevalence and clinical significance in a series of 74 patients. Lupus, 2004, 13, 245-248.	0.8	53
93	Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome. Rheumatology, 2010, 49, 940-944.	0.9	53
94	Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity. Lupus, 2017, 26, 163-169.	0.8	53
95	18F-FDG PET/CT in patients with amyloid light-chain amyloidosis: case-series and literature review. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2012, 19, 94-98.	1.4	52
96	Study of Anti-Mþllerian Hormone and Its Relation to the Subsequent Probability of Pregnancy in 112 Patients With Systemic Lupus Erythematosus, Exposed or Not to Cyclophosphamide. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 3785-3792.	1.8	51
97	Efficacy of anti-TNF alpha in severe and refractory major vessel involvement of Behcet's disease: A multicenter observational study of 18 patients. Clinical Immunology, 2018, 197, 54-59.	1.4	51
98	Intravenous immunoglobulins in systemic sclerosis: Data from a French nationwide cohort of 46 patients and review of the literature. Autoimmunity Reviews, 2017, 16, 377-384.	2.5	49
99	Recommendations for using TNFî± antagonists and French Clinical Practice Guidelines endorsed by the French National Authority for Health. Joint Bone Spine, 2013, 80, 574-581.	0.8	48
100	Immunological profiles determine neurological involvement in Sjögren's syndrome. European Journal of Internal Medicine, 2014, 25, 177-181.	1.0	48
101	Deletion of either CD55 or CD97 ameliorates arthritis in mouse models. Arthritis and Rheumatism, 2010, 62, 1036-1042.	6.7	47
102	Clinical phenotypes and survival of pre-capillary pulmonary hypertension in systemic sclerosis. PLoS ONE, 2018, 13, e0197112.	1.1	47
103	Presence of microchimerism in labial salivary glands in systemic sclerosis but not in Sjögren's syndrome. Arthritis and Rheumatism, 2002, 46, 1039-1043.	6.7	46
104	Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1- <i>b</i>][1,3]oxazoles for Neglected Tropical Diseases: Structure–Activity Studies on a Preclinical Candidate for Visceral Leishmaniasis. Journal of Medicinal Chemistry, 2016, 59, 2530-2550.	2.9	46
105	Spectrum and Prognosis of Noninfectious Renal Mixed Cryoglobulinemic GN. Journal of the American Society of Nephrology: JASN, 2016, 27, 1213-1224.	3.0	44
106	Efficacy of Anti-TNFα in Severe and Refractory Neuro-Behcet Disease. Medicine (United States), 2016, 95, e3550.	0.4	43
107	Lung and heart-lung transplantation for systemic sclerosis patients. A monocentric experience of 13 patients, review of the literature and position paper of a multidisciplinary Working Group. Presse Medicale, 2014, 43, e345-e363.	0.8	42
108	Hereditary angioedema with normal C1 inhibitor and factor XII mutation: a series of 57 patients from the French National Center of Reference for Angioedema. Clinical and Experimental Immunology, 2016, 185, 332-337.	1.1	42

#	Article	IF	CITATIONS
109	Threeâ€dimensional electron microscopy of entire cells. Journal of Microscopy, 1990, 157, 115-126.	0.8	41
110	Scleroderma Lung Disease. Clinical Reviews in Allergy and Immunology, 2011, 40, 104-116.	2.9	41
111	Angiopoietin-2 promotes inflammatory activation of human macrophages and is essential for murine experimental arthritis. Annals of the Rheumatic Diseases, 2012, 71, 1402-1417.	0.5	41
112	Primary Sjögren's syndrome in men. Scandinavian Journal of Rheumatology, 2008, 37, 300-305.	0.6	40
113	Pulmonary arterial hypertension in idiopathic inflammatory myopathies. Medicine (United States), 2016, 95, e4911.	0.4	40
114	Plasminogen gene mutation with normal C1 inhibitor hereditary angioedema: Three additional French families. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 2237-2239.	2.7	40
115	Association between systemic sclerosis and breast cancer: eight new cases and review of the literature. Clinical Rheumatology, 2004, 23, 516-522.	1.0	39
116	Pneumocystis jirovecii colonization in patients with systemic autoimmune diseases: prevalence, risk factors of colonization and outcome. Rheumatology, 2011, 50, 569-577.	0.9	39
117	Autologous Hematopoietic Stem Cell Transplant in Systemic Sclerosis: Quantitative High Resolution Computed Tomography of the Chest Scoring. Journal of Rheumatology, 2009, 36, 1460-1463.	1.0	38
118	Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH). Current Rheumatology Reports, 2016, 18, 10.	2.1	38
119	Seronegative polyarthritis revealing antisynthetase syndrome: a multicentre study of 40 patients. Rheumatology, 2015, 54, 927-932.	0.9	37
120	CD3-CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder. Haematologica, 2015, 100, 1086-95.	1.7	37
121	Treatment of HAE Attacks in the Icatibant Outcome Survey: An Analysis of Icatibant Self-Administration versus Administration by Health Care Professionals. International Archives of Allergy and Immunology, 2015, 167, 21-28.	0.9	37
122	Role of B cells in the pathogenesis of systemic sclerosis. Revue De Medecine Interne, 2017, 38, 113-124.	0.6	37
123	French recommendations for the management of systemic sclerosis. Orphanet Journal of Rare Diseases, 2021, 16, 322.	1.2	37
124	Risk factors for severe bacterial infections in patients with systemic autoimmune diseases receiving rituximab. Clinical Rheumatology, 2014, 33, 799-805.	1.0	35
125	Strains Responsible for Invasive Meningococcal Disease in Patients With Terminal Complement Pathway Deficiencies. Journal of Infectious Diseases, 2017, 215, 1331-1338.	1.9	35
126	Serum free light chains of immunoglobulins as biomarkers for systemic sclerosis characteristics, activity and severity. Autoimmunity Reviews, 2014, 13, 974-980.	2.5	34

#	Article	IF	CITATIONS
127	Aminothiazoles: Hit to lead development to identify antileishmanial agents. European Journal of Medicinal Chemistry, 2015, 102, 582-593.	2.6	34
128	An international SUrvey on non-iNvaSive tecHniques to assess the mlcrocirculation in patients with RayNaud's phEnomenon (SUNSHINE survey). Rheumatology International, 2017, 37, 1879-1890.	1.5	33
129	Combined pulmonary fibrosis and emphysema in systemic sclerosis: A syndrome associated with heavy morbidity and mortality. Seminars in Arthritis and Rheumatism, 2019, 49, 98-104.	1.6	33
130	Male microchimerism and HLA compatibility in French women with sclerodema: a different profile in limited and diffuse subset. Rheumatology, 2009, 48, 363-366.	0.9	32
131	Biologics in myelodysplastic syndrome-related systemic inflammatory and autoimmune diseases: French multicenter retrospective study of 29 patients. Autoimmunity Reviews, 2017, 16, 903-910.	2.5	32
132	Cytokine concentrations in exhaled breath condensates in systemic sclerosis. Inflammation Research, 2008, 57, 151-156.	1.6	31
133	Effect of In Vitro and In Vivo Anakinra on Cytokines Production in Schnitzler Syndrome. PLoS ONE, 2013, 8, e59327.	1.1	31
134	Hereditary angioedema with <i>F12</i> mutation: factors modifying the clinical phenotype. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 1659-1665.	2.7	31
135	Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The <scp>OPuS</scp> â€2Âstudy. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1871-1880.	2.7	31
136	Comparison of the Farr radioimmunoassay, 3 commercial enzyme immunoassays and Crithidia luciliae immunofluorescence test for diagnosis and activity assessment of systemic lupus erythematosus. Clinica Chimica Acta, 2010, 411, 959-964.	0.5	30
137	Thrombotic events during long-term follow-up of obstetric antiphospholipid syndrome patients. Lupus, 2011, 20, 861-865.	0.8	30
138	Digestive-tract sarcoidosis. Medicine (United States), 2016, 95, e4279.	0.4	30
139	TAFRO Syndrome in Caucasians: A Case Report and Review of the Literature. Frontiers in Medicine, 2017, 4, 149.	1.2	30
140	In vitro metabolism, disposition, preclinical pharmacokinetics and prediction of human pharmacokinetics of DNDI-VL-2098, a potential oral treatment for Visceral Leishmaniasis. European Journal of Pharmaceutical Sciences, 2014, 65, 147-155.	1.9	29
141	Neutrophilic Dermatoses in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Medicine (United States), 2016, 95, e2957.	0.4	29
142	Proinflammatory B-cell profile in the early phases of MS predicts an active disease. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e431.	3.1	29
143	Clinical phenotypes of extrapulmonary sarcoidosis: an analysis of a French, multi-ethnic, multicentre cohort. European Respiratory Journal, 2021, 57, 2001160.	3.1	29
144	Aerosolized iloprost in CREST syndrome related pulmonary hypertension. Journal of Rheumatology, 2001, 28, 2252-6.	1.0	29

#	Article	lF	CITATIONS
145	Hereditary angioedema with normal C1 inhibitor in a French cohort: Clinical characteristics and response to treatment with icatibant. Immunity, Inflammation and Disease, 2017, 5, 29-36.	1.3	27
146	Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database. Oncolmmunology, 2020, 9, 1722022.	2.1	27
147	A Rac1 inhibitory peptide suppresses antibody production and paw swelling in the murine collagen-induced arthritis model of rheumatoid arthritis. Arthritis Research and Therapy, 2010, 12, R2.	1.6	26
148	Design, synthesis, ADME characterization and antileishmanial evaluation of novel substituted quinoline analogs. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2046-2052.	1.0	26
149	Value of the Overall Pneumococcal Polysaccharide Response in the Diagnosis of Primary Humoral Immunodeficiencies. Frontiers in Immunology, 2017, 8, 1862.	2.2	26
150	Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease. Arthritis and Rheumatology, 2021, 73, 295-304.	2.9	26
151	Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population. Rheumatology, 2015, 54, 1262-1269.	0.9	25
152	Diagnosis of primary antibody and complement deficiencies in young adults after a first invasive bacterial infection. Clinical Microbiology and Infection, 2017, 23, 576.e1-576.e5.	2.8	25
153	Bleeding complications and antithrombotic treatment in 264 pregnancies in antiphospholipid syndrome. Lupus, 2018, 27, 1679-1686.	0.8	25
154	Ulnar Artery Occlusion and Severity Markers of Vasculopathy in Systemic Sclerosis: A Multicenter Crossâ€Sectional Study. Arthritis and Rheumatology, 2019, 71, 983-990.	2.9	25
155	Serious Infectious Events and Immunoglobulin Replacement Therapy in Patients With Autoimmune Disease Receiving Rituximab: A Retrospective Cohort Study. Clinical Infectious Diseases, 2021, 72, 727-737.	2.9	25
156	Scleromyxedema (lichen myxedematosus) associated with dermatomyositis. British Journal of Dermatology, 2001, 144, 359-362.	1.4	24
157	High Throughput Physical Organic Chemistry:  Analytical Constructs for Monomer Reactivity Profiling. ACS Combinatorial Science, 2005, 7, 554-560.	3.3	24
158	Hereditary angioedema with normal C1 inhibitor: clinical characteristics and treatment response with plasma-derived human C1 inhibitor concentrate (Berinert®) in a French cohort. European Journal of Dermatology, 2017, 27, 155-159.	0.3	24
159	Renal Pathologic Findings in TAFRO Syndrome: Is There a Continuum Between Thrombotic Microangiopathy and Membranoproliferative Glomerulonephritis? A Case Report and Literature Review. Frontiers in Immunology, 2019, 10, 1489.	2.2	24
160	Predictors of early relapse in patients with non-infectious mixed cryoglobulinemia vasculitis: Results from the French nationwide CryoVas survey. Autoimmunity Reviews, 2014, 13, 630-634.	2.5	23
161	Reemergence of Splenectomy for ITP Second-line Treatment?. Annals of Surgery, 2016, 264, 772-777.	2.1	23
162	Factors associated with the 6-minute walk distance in patients with systemic sclerosis. Arthritis Research and Therapy, 2017, 19, 279.	1.6	22

#	Article	IF	Citations
163	Pulmonary arterial hypertension in ANCA-associated vasculitis. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2006, 23, 223-8.	0.2	22
164	The Icatibant Outcome Survey: experience of hereditary angioedema management from six European countries. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1214-1222.	1.3	21
165	Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patients. Journal of Psychosomatic Research. 2020. 135, 110132.	1.2	21
166	Pneumatic transport is critical for leukaemic patients with major leukocytosis: what precautions to measure lactate dehydrogenase, potassium and aspartate aminotransferase?. Annals of Clinical Biochemistry, 2010, 47, 94-96.	0.8	20
167	Local Synovial Engagement of Angiogenic TIEâ€2 Is Associated With the Development of Persistent Erosive Rheumatoid Arthritis in Patients With Early Arthritis. Arthritis and Rheumatism, 2013, 65, 3073-3083.	6.7	20
168	Early trajectories of skin thickening are associated with severity and mortality in systemic sclerosis. Arthritis Research and Therapy, 2020, 22, 30.	1.6	20
169	18F-FDG positron emission tomography scanning in systemic sclerosis-associated interstitial lung disease: a pilot study. Arthritis Research and Therapy, 2021, 23, 76.	1.6	20
170	Rituximab in Postpartum-Related Acquired Hemophilia. American Journal of Medicine, 2006, 119, 86-88.	0.6	19
171	The Ras guanine nucleotide exchange factor RasGRF1 promotes matrix metalloproteinase-3 production in rheumatoid arthritis synovial tissue. Arthritis Research and Therapy, 2009, 11, R121.	1.6	19
172	Analysis of characteristics associated with reinjection of icatibant: Results from the Icatibant Outcome Survey. Allergy and Asthma Proceedings, 2015, 36, 399-406.	1.0	19
173	Special considerations in pregnant systemic sclerosis patients. Expert Review of Clinical Immunology, 2016, 12, 1161-1173.	1.3	19
174	Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines. RMD Open, 2019, 4, e000784.	1.8	19
175	Distinctive Patterns of Transthyretin Amyloid in Salivary Tissue. American Journal of Surgical Pathology, 2015, 39, 1035-1044.	2.1	18
176	Silencing the Expression of Ras Family GTPase Homologues Decreases Inflammation and Joint Destruction in Experimental Arthritis. American Journal of Pathology, 2010, 177, 3010-3024.	1.9	17
177	Disseminated Infection Caused by <i>Francisella philomiragia </i> , France, 2014. Emerging Infectious Diseases, 2012, 21, 2260-2261.	2.0	17
178	A French National Survey on Clotting Disorders in Mastocytosis. Medicine (United States), 2015, 94, e1414.	0.4	17
179	Role of Stromelysin 2 (Matrix Metalloproteinase 10) as a Novel Mediator of Vascular Remodeling Underlying Pulmonary Hypertension Associated With Systemic Sclerosis. Arthritis and Rheumatology, 2017, 69, 2209-2221.	2.9	17
180	Association between Rheumatoid Arthritis and Pulmonary Hypertension: Data from the French Pulmonary Hypertension Registry. Respiration, 2018, 95, 244-250.	1.2	17

#	Article	IF	CITATIONS
181	Validation of the Social Appearance Anxiety Scale in Patients With Systemic Sclerosis: A Scleroderma Patientâ€Centered Intervention Network Cohort Study. Arthritis Care and Research, 2018, 70, 1557-1562.	1.5	17
182	Prevalence and Clinical Associations of Antiphospholipid Antibodies in Systemic Sclerosis: New Data From a French Cross-Sectional Study, Systematic Review, and Meta-Analysis. Frontiers in Immunology, 2018, 9, 2457.	2.2	17
183	Pulmonary-renal syndrome due to hemorrhagic fever with renal syndrome: an unusual manifestation of Puumala virus infection in France. Clinical Nephrology, 2003, 59, 297-300.	0.4	17
184	Relationship between parity and clinical and biological features in patients with systemic sclerosis. Journal of Rheumatology, 2001, 28, 509-13.	1.0	17
185	N-terminal pro-brain natriuretic peptide is a strong predictor of mortality in systemic sclerosis. International Journal of Cardiology, 2016, 223, 385-389.	0.8	16
186	A prospective study of the 6â€min walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment-naÃ⁻ve systemic sclerosis-associated pulmonary arterial hypertension. Annals of the Rheumatic Diseases, 2016, 75, 1457-1465.	0.5	16
187	Longâ€term safety of icatibant treatment of patients with angioedema in realâ€world clinical practice. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 994-998.	2.7	16
188	Aortic aneurysm in MAGIC syndrome successfully managed with combined anti-TNF-Â and stent grafting. Rheumatology, 2009, 48, 1169-1170.	0.9	15
189	Graft-versus-host disease-related polymyositis. Clinical Rheumatology, 2010, 29, 431-433.	1.0	15
190	Sustained T cell Rap1 signaling is protective in the collagenâ€induced arthritis model of rheumatoid arthritis. Arthritis and Rheumatism, 2010, 62, 3289-3299.	6.7	15
191	Specific Polysaccharide Antibody Deficiency Revealed by Severe Bacterial Infections in Adulthood: A Report on 11 Cases. Clinical Infectious Diseases, 2017, 65, 328-331.	2.9	15
192	Relevance of Partitioning DLCO to Detect Pulmonary Hypertension in Systemic Sclerosis. PLoS ONE, 2013, 8, e78001.	1.1	15
193	Effective immune restoration after immunosuppressant discontinuation in a lupus patient presenting progressive multifocal leukoencephalopathy. Journal of the Neurological Sciences, 2009, 287, 246-249.	0.3	14
194	Factors associated with hospital admission in hereditary angioedema attacks: a multicenter prospective study. Annals of Allergy, Asthma and Immunology, 2015, 114, 499-503.	0.5	14
195	Mycophenolate mofetil following cyclophosphamide in worsening systemic sclerosis-associated interstitial lung disease. Journal of Scleroderma and Related Disorders, 2016, 1, 234-240.	1.0	14
196	B Cell Homeostasis and Functional Properties Are Altered in an Hypochlorous Acid-Induced Murine Model of Systemic Sclerosis. Frontiers in Immunology, 2017, 8, 53.	2.2	14
197	Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the Icatibant Outcome Survey. Allergy, Asthma and Clinical Immunology, 2017, 13, 31.	0.9	14
198	Anticoagulation withdrawal in antiphospholipid syndrome: a retrospective matched-control study. Lupus, 2018, 27, 357-364.	0.8	14

#	Article	IF	CITATIONS
199	Limited Exercise Capacity in Patients with Systemic Sclerosis: Identifying Contributing Factors with Cardiopulmonary Exercise Testing. Journal of Rheumatology, 2018, 45, 95-102.	1.0	14
200	Whole-Body Distribution and Clinical Association of Telangiectases in Systemic Sclerosis. JAMA Dermatology, 2018, 154, 796.	2.0	14
201	Thoracic involvement and imaging patterns in IgG4-related disease. European Respiratory Review, 2021, 30, 210078.	3.0	14
202	A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study. Microvascular Research, 2015, 102, 19-24.	1.1	13
203	Antiphospholipid Syndrome With Isolated Isotype M Anticardiolipin and/or Anti-B2GPI Antibody Is Associated With Stroke. Stroke, 2018, 49, 2770-2772.	1.0	13
204	Angioedema associated with thrombolysis for ischemic stroke: analysis of a caseâ€control study. Journal of Internal Medicine, 2019, 286, 702-710.	2.7	13
205	Survival Improved in Patients AgedÂâ‰ず0 Years With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension During the Period 2006 to 2017 in France. Chest, 2020, 157, 945-954.	0.4	13
206	Sausage-like toe and heel pain: value for diagnosing and evaluating the severity of spondyloarthropathies defined by Amor's criteria. A retrospective study in 161 patients. Joint Bone Spine, 2002, 69, 574-579.	0.8	12
207	Consultation/liaison psychiatry practice: combined medical and psychiatric consultations. Journal of Psychosomatic Research, 2007, 63, 219-220.	1.2	12
208	Extended myositis-specific and -associated antibodies profile in systemic sclerosis: A cross-sectional study. Joint Bone Spine, 2021, 88, 105048.	0.8	12
209	Mixed connective tissue disease presenting as trigeminal neuropathy. Acta Neurologica Belgica, 2014, 114, 245-246.	0.5	11
210	Evolution of high-resolution CT-scan in systemic sclerosis-associated interstitial lung disease: Description and prognosis factors. Seminars in Arthritis and Rheumatism, 2020, 50, 1406-1413.	1.6	11
211	Extensive levamisole-induced vasculitis. Clinical and Experimental Dermatology, 2017, 42, 413-415.	0.6	10
212	Combined measurement of carbon monoxide and nitric oxide lung transfer does not improve the identification of pulmonary hypertension in systemic sclerosis. European Respiratory Journal, 2017, 50, 1701008.	3.1	10
213	Sarcoidosis diagnosed on granulomas in the explanted heart after transplantation: Results of a French nationwide study. International Journal of Cardiology, 2020, 307, 94-100.	0.8	10
214	Anti–programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study. European Journal of Cancer, 2022, 160, 134-139.	1.3	10
215	Interstitial pneumonia with autoimmune features: Evaluation of connective tissue disease incidence during follow-up. European Journal of Internal Medicine, 2022, 97, 62-68.	1.0	10
216	Can Antinuclear Antibodies Have a Pathogenic Role in Systemic Sclerosis?. Frontiers in Immunology, 0, 13, .	2.2	10

#	Article	IF	CITATIONS
217	Systemic sclerosis and prevalence of monoclonal immunoglobulin. Autoimmunity Reviews, 2014, 13, 1189-1194.	2.5	9
218	An Optimized Fluorescence-Based Bidimensional Immunoproteomic Approach for Accurate Screening of Autoantibodies. PLoS ONE, 2015, 10, e0132142.	1.1	9
219	Gentle blood aspiration and tube cushioning reduce pneumatic tube system interference in lactate dehydrogenase assays. Annals of Clinical Biochemistry, 2016, 53, 295-297.	0.8	9
220	Haemodynamically proven pulmonary hypertension in a patient with GATA2 deficiency-associated pulmonary alveolar proteinosis and fibrosis. European Respiratory Journal, 2017, 49, 1700178.	3.1	9
221	Schnitzler syndrome co-occurring with idiopathic multicentric Castleman disease that responds to anti-IL-1 therapy: A case report and clue to pathophysiology. Current Research in Translational Medicine, 2018, 66, 83-86.	1.2	9
222	lgG4-related disease and hypereosinophilic syndrome: Overlapping phenotypes. Autoimmunity Reviews, 2021, 20, 102889.	2.5	9
223	Reliability and Validity of Three Versions of the Brief Fear of Negative Evaluation Scale in Patients With Systemic Sclerosis: A Scleroderma Patient entered Intervention Network Cohort Study. Arthritis Care and Research, 2018, 70, 1646-1652.	1.5	8
224	Adherence to hydroxychloroquine in patients with systemic lupus: Contrasting results and weak correlation between assessment tools. Joint Bone Spine, 2020, 87, 603-610.	0.8	8
225	Association between Leflunomide and Pulmonary Hypertension. Annals of the American Thoracic Society, 2021, 18, 1306-1315.	1.5	8
226	Large granular lymphocyte leukaemia associated with systemic sclerosis. British Journal of Rheumatology, 2004, 43, 1197-1198.	2.5	7
227	Letter to the Editor. Lupus, 2006, 15, 114-115.	0.8	7
228	Periorbital Ecchymoses Are Not Pathognomonic of the Light-chain Type of Amyloidosis. Acta Dermato-Venereologica, 2007, 87, 544-545.	0.6	7
229	Assessment of T-cell polarization onÂthe basis of surface marker expression: Diagnosis and potential therapeutic implications in lymphocytic variant hypereosinophilic syndrome. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 1110-1114.e2.	2.0	7
230	Conseils d'utilisation des traitements anti-TNF et recommandations nationales de bonne pratique labellisées par la Haute Autorité de santé française. Revue Du Rhumatisme (Edition Francaise), 2013, 80, 459-466.	0.0	6
231	Mastocytosis among elderly patients. Medicine (United States), 2016, 95, e3901.	0.4	6
232	Diagnosis and treatment of upper airway oedema caused by acute angio-oedema in the emergency department: a French consensus statement. European Journal of Emergency Medicine, 2017, 24, 318-325.	0.5	6
233	Specialist Advice Support for Management of Severe Hereditary Angioedema Attacks: A Multicenter Cluster-Randomized Controlled Trial. Annals of Emergency Medicine, 2018, 72, 194-203.e1.	0.3	6
234	Hereditary angioedema, emergency management of attacks by a call center. European Journal of Internal Medicine, 2019, 67, 42-46.	1.0	6

#	Article	IF	Citations
235	Dyslipidemia is insufficiently treated in antiphospholipid syndrome patients. Lupus, 2022, 31, 1379-1384.	0.8	6
236	Simple gene signature to assess murine fibroblast polarization. Scientific Reports, 2022, 12, .	1.6	6
237	Dedicated call center (SOS-HAE) for hereditary angioedema attacks: study protocol for a randomised controlled trial. Trials, 2016, 17, 225.	0.7	5
238	Normal PAI-2 level in French FXII-HAE patients. Journal of Allergy and Clinical Immunology, 2017, 139, 1719-1720.	1.5	5
239	Autologous Hematopoietic Stem Cell Transplantation Versus Intravenous Pulse Therapy Cyclophosphamide for Severe or Rapidly Progressive Systemic Sclerosis, the Astis Trial. Blood, 2012, 120, 964-964.	0.6	5
240	Attenuated androgen discontinuation in patients with hereditary angioedema: a commented case series. Allergy, Asthma and Clinical Immunology, 2022, 18, 4.	0.9	5
241	A Four-Year History of Pruriginous Erythroderma Leading to the Diagnosis of Idiopathic Hypereosinophilic Syndrome. Acta Dermato-Venereologica, 2002, 82, 376-378.	0.6	4
242	Beneficial effect of intravenous immunoglobulins on systemic capillary leak syndrome in patients with monoclonal gammopathy. Critical Care Medicine, 2009, 37, 795.	0.4	4
243	Factor structure and convergent validity of the Derriford Appearance Scale-24 using standard scoring versus treating â€`not applicable' responses as missing data: a Scleroderma Patient-centered Intervention Network (SPIN) cohort study. BMJ Open, 2018, 8, e018641.	0.8	4
244	Oral Plasma Kallikrein Inhibitor BCX7353 is Safe and Effective as an On-Demand Treatment of Angioedema Attacks in Hereditary Angioedema (HAE) Patients: Results of the ZENITH-1 Trial. Journal of Allergy and Clinical Immunology, 2019, 143, AB36.	1.5	4
245	Hereditary Angioedema with and Without C1-Inhibitor Deficiency in Postmenopausal Women. Journal of Clinical Immunology, 2021, 41, 163-170.	2.0	4
246	Fatal Enterovirus-related Myocarditis in a Patient with Devic's Syndrome Treated with Rituximab. Cardiac Failure Review, 2021, 7, e09.	1.2	4
247	Polyarteritis nodosa-related coronary aneurysms. Journal of Rheumatology, 2008, 35, 933-4.	1.0	4
248	Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study. Clinical and Translational Allergy, 2018, 8, 11.	1.4	3
249	Hereditary angioedema: Clinical presentation and socioeconomic cost of 200 French patients. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 328-330.	2.0	3
250	Remission of Refractory Systemic-Onset Juvenile Idiopathic Arthritis After Treatment With Siltuximab. Journal of Clinical Rheumatology, 2019, 25, e40-e42.	0.5	3
251	Are pregnancies with lupus but without APS of good prognosis?. Autoimmunity Reviews, 2020, 19, 102489.	2.5	3
252	Systemic Pulmonary Events Associated with Myelodysplastic Syndromes: A Retrospective Multicentre Study. Journal of Clinical Medicine, 2021, 10, 1162.	1.0	3

#	Article	IF	CITATIONS
253	Treatment of Advanced Systemic Mastocytosis with PKC412: The French Compassionate Use Programme Experience and Historical Comparison. Blood, 2014, 124, 3193-3193.	0.6	3
254	Role of Iconographic Examinations in the Treatment Algorithm in Erdheim-Chester Disease. Journal of Clinical Oncology, 2011, 29, 4466-4467.	0.8	2
255	FRIO245â€Survival and prognostic factors in patients with incident systemic sclerosis-associated pulmonary arterial hypertension from the french registry. Annals of the Rheumatic Diseases, 2013, 71, 397.1-397.	0.5	2
256	Time for precision medicine in systemic sclerosis-associated pulmonary arterial hypertension. European Respiratory Journal, 2021, 57, 2100205.	3.1	2
257	Effective Anti–SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1356-1364.e2.	2.0	2
258	An unusual cause of vascular purpura: recurrent cutaneous eosinophilic necrotizing vasculitis. Acta Dermato-Venereologica, 2000, 80, 394-5.	0.6	2
259	Consideration of coping strategies for patients suffering from systemic lupus erythematosus: reflection for a personalised practice of patient education. Clinical and Experimental Rheumatology, 2020, 38, 705-712.	0.4	2
260	Bosentan for the treatment of scleroderma. Future Rheumatology, 2006, 1, 549-562.	0.2	1
261	Is Pulmonary Arterial Hypertension Really a Late Complication of Systemic Sclerosis?. Chest, 2010, 138, 462-463.	0.4	1
262	Osteolytic Lesion with Thick Sclerotic Walls and Demyelinating Polyneuropathy. Journal of Rheumatology, 2012, 39, 2175-2176.	1.0	1
263	AB0614â€Prognostic Factors of Functional Outcome in Systemic Sclerosis-Associated Interstitial Lung Disease. Annals of the Rheumatic Diseases, 2014, 73, 1008.4-1009.	0.5	1
264	Hereditary Angioedema: Clinical Characteristics and Treatment Response with Berinert in a French Cohort in Patient Under 16 Years Old. Journal of Allergy and Clinical Immunology, 2015, 135, AB193.	1.5	1
265	OP0059â€Phenotypes Determined by Cluster Analysis and their Survival in the Prospective Eustar Cohort of Patients with Systemic Sclerosis. Annals of the Rheumatic Diseases, 2015, 74, 90.1-90.	0.5	1
266	Reply to Gilchrist et al. and to Musher. Clinical Infectious Diseases, 2018, 66, 637-638.	2.9	1
267	Characteristics of patients with systemic sclerosis suffering from a lower limb amputation: Results of a French collaborative study. Journal of Scleroderma and Related Disorders, 2020, 5, 224-230.	1.0	1
268	Mast Cell Disease and Blood Coagulation Abnormalities: Discussion on 14 Cases and Review of the Literature. Blood, 2014, 124, 2856-2856.	0.6	1
269	Multiplex reverse transcription polymerase chain reaction assessment of sialyltransferase expression in peripheral blood mononuclear cells in systemic sclerosis. Journal of Rheumatology, 2004, 31, 88-95.	1.0	1
270	Long-term prophylaxis with lanadelumab for HAE: authorization for temporary use in France. Allergy, Asthma and Clinical Immunology, 2022, 18, 30.	0.9	1

#	Article	IF	Citations
271	Effects of Immunoglobulins G From Systemic Sclerosis Patients in Normal Dermal Fibroblasts: A Multi-Omics Study. Frontiers in Immunology, 0, 13, .	2.2	1
272	Atteinte cardiaque de la maladie de Fabry. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2005, 2005, 23-27.	0.0	0
273	Place du bosentan dans le traitement de l'hypertension artérielle pulmonaire de la sclérodermie systémique. Revue De Medecine Interne, 2007, 28, S221-S226.	0.6	0
274	HTAP des connectivites. Revue Des Maladies Respiratoires Actualites, 2009, 1, 172-174.	0.0	0
275	Clinical Characteristics And Survival Of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension Diagnosed By A Systematic Detection Program. , 2011, , .		0
276	FRIO254â€Prognosis factors for survival and progression-free survival in systemic sclerosis–associated interstitial lung disease. Annals of the Rheumatic Diseases, 2013, 71, 400.1-400.	0.5	0
277	Maladies systémiques et vascularites. , 2013, , 219-258.		0
278	Histiocytoses., 2013,, 685-712.		0
279	FRIO479â€Serum Free Light Chains of Immunoglobulins Are Associated with Disease Activity in Systemic Sclerosis: A Prospective and Controlled Study. Annals of the Rheumatic Diseases, 2014, 73, 560.3-560.	0.5	0
280	OP0096â€Relevance of the 6-Minute Walking Test in Assessing the Severity of Pulmonary Arterial Hypertension Associated with Systemic Sclerosis, without Interstitial Lung Disease. Annals of the Rheumatic Diseases, 2014, 73, 97.3-98.	0.5	0
281	To Spare or Not to Spare…? The Aortic Valve in Scleroderma and Aortic Root Aneurysm. Journal of Cardiac Surgery, 2014, 29, 55-58.	0.3	0
282	SAT0543 lgg4-Related Disease: Clinical and Biological Characteristics in 90 Patients from a Large Multicentric National Registry. Annals of the Rheumatic Diseases, 2015, 74, 857.1-857.	0.5	0
283	FRIO509â€Chromosome 22Q11.2 Deletion Syndrome (Digeorge Syndrome) and Autoimmunity: A French Retrospective Pediatric Study of 15 Cases. Annals of the Rheumatic Diseases, 2015, 74, 613.2-613.	0.5	0
284	Actualités en allergologieÂ: médecine interne. Revue Francaise D'allergologie, 2015, 55, 207-209.	0.1	0
285	FRIO299â€Pulmonary Arterial Hypertension in Idiopathic Inflammatory Myopathies: Data from The French Pulmonary Hypertension Registry and Review of The Literature. Annals of the Rheumatic Diseases, 2016, 75, 543.2-543.	0.5	0
286	A New Era in the Treatment of Scleroderma-associated Interstitial Lung Disease?. Journal of Rheumatology, 2016, 43, 1619-1621.	1.0	0
287	Clinical characteristics and response to attack treatment with Berinert \hat{A}^{\otimes} of drug induced angioedema in the French Cohort COBRA Journal of Allergy and Clinical Immunology, 2017, 139, AB236.	1.5	0
288	OP0236â€Benefit and safety of antithrombotic treatment in 264 pregnancies in patients with antiphospholipid syndrome. , 2017, , .		0

#	Article	IF	CITATIONS
289	Hypertension pulmonaire et connectivites. Revue Du Rhumatisme Monographies, 2018, 85, 210-220.	0.0	O
290	Incidence and Risk Factors for Secondary Autoimmune Diseases (AD) After Hematopoietic Stem Cell Transplantation (HSCT) for a Severe Autoimmune Disease-A Retrospective EBMT WP AD Study. Blood, 2010, 116, 2322-2322.	0.6	0
291	A Scleroderma Patient Presenting with Facial Pain. , 2011, , 293-298.		0
292	Safety Profile Of Bortezomib Impacts Survival Of Cardiac AL Amyloidosis. Blood, 2013, 122, 5316-5316.	0.6	0
293	Scanning Transmission and Computer-Aided Volumic Electron Microscopy: 3D Modeling of Entire Cells by Electronic Imaging. Proceedings Annual Meeting Electron Microscopy Society of America, 1990, 48, 468-469.	0.0	0
294	Safety Profile of Bortezomib Impacts Survival in Light Chain Amyloidosis. Blood, 2014, 124, 5664-5664.	0.6	0
295	Systemic Inflammatory and Autoimmune Diseases (SAID) Associated with MDS: A French Multicenter Retrospective Study. Blood, 2014, 124, 3254-3254.	0.6	0
296	SAT0472â€Ulnar occlusion is a marker of global vascular damage in systemic sclerosis: results from a monocentric prospective study of 99 patients. , 2018, , .		0
297	Passages in culture and stimulation conditions influence protein expression of primary fibroblasts. Proteomics, 2021, , 2100116.	1.3	0
298	The letter responds to comment on: Anti-PD(L)1 immunotherapies in patients with cancer and with pre-existing systemic sclerosis: a post-marketed safety assessment study. European Journal of Cancer, 2022, 165, 208-209.	1.3	0